Forschungsartikel
1. Sadeghimehr M, Bertisch B, Negro F, Butsashvili M, Shilton S, Tskhomelidze I, Tsereteli M, Keiser O, Estill J. Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and costeffectiveness analysis. Peer J. 2021 Sep 10;9:e11895.
2. Roelens M, Bertisch B, Moradpour D, Cerny A, Semmo N, Schmid P, Müllhaupt B, Clerc O, Semela D, Junker C, Negro F, Keiser O; Swiss Hepatitis C Cohort Study. All-cause mortality and causes of death in the Swiss Hepatitis C Cohort Study (SCCS). Open Forum Infect Dis. 2020 Jul 25;7(8):ofaa308.
3. Sadeghimehr M, Bertisch B, Schaetti C, Wandeler G, Richard JL, Scheidegger C, Keiser O, Estill J. Modelling the impact of different testing strategies for HCV infection in Switzerland. J Virus Erad. 2019 Nov 4;5(4):191-203.
4. Combes JD, Clifford GM, Günthard HF, Hauser C, Darling KEA, Valladares P, Battegay M, Waldeck F, Bernasconi E, Bertisch B, Hirsch HH, Brenner N, Waterboer T, Scherrer AU; Swiss HIV Cohort Study. Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. Int J Cancer. 2020 Aug 1;147(3):757-765.
5. Raben D, Sullivan AK, Mocroft A, Kutsyna G, Hadžiosmanovic V, Vassilenko A, Chkhartisvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L, Farazmand P, Pesut D, De Wit S, Gatell JM, Gazzard B, d’Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD; HIDES Study Group. Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015. PLoS One. 2019 Aug 13;14(8):e0220108.
6. Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, Azziz-Baumgartner E, Bajjou T, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Chinbayar T, Cilloniz C, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hu XY, Islam QT, Jiménez MF, Keijzers G, Khalili H, Kusznierz G, Kuzman I, Langenegger E, Lankarani KB, Leo YS, Libster RP, Linko R, Madanat F, Maltezos E, Mamun A, Manabe T, Metan G, Mickiene A, Mikic D, Mohn KGI, Oliva ME, Ozkan M, Parekh D, Paul M, Rath BA, Refaey S, Rodríguez AH, Sertogullarindan B, Skręt-Magierło J, Somer A, Talarek E, Tang JW, To K, Tran D, Uyeki TM, Vaudry W, Vidmar T, Zarogoulidis P; PRIDE Consortium Investigators, Nguyen-Van-Tam JS. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. .J Infect Dis. 2020 Jan 14;221(3):356-366.
7. Brezzi M, Bertisch B, Roelens M, Moradpour D, Terziroli Beretta-Piccoli B, Semmo N, Müllhaupt B, Semela D, Negro F, Keiser O; Swiss Hepatitis C Cohort Study. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study..PLoS One. 2019 Jun 24;14(6):e0218706.
8. Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, Schmid P, Giudici F, Clerc O, Moriggia A, Roelens M, Marinucci F, Zehnder C, Moradpour D, Keiser O; Swiss Hepatitis C Cohort Study. Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?.Clin Infect Dis. 2020 Feb 3;70(4):653-659.
9. Braun DL, Turk T, Tschumi F, Grube C, Hampel B, Depmeier C, Schreiber PW, Brugger SD, Greiner M, Steffens D, De Torrenté-Bayard C, Courlet P, Neumann K, Kuster H, Flepp M, Bertisch B, Decosterd L, Böni J, Metzner KJ, Kouyos RD, Günthard HF. No inferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial.Clin Infect Dis. 2019 Oct 15;69(9):1489-1497.
10. Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour JF, Moradpour D, Bruggmann P, Terziroli Beretta-Piccoli B, Semela D, Brezzi M, Bertisch B, Estill J, Negro F, Spoerri A; Swiss Hepatititis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat 2018;25(2):152-160.
11. Blaser N, Bertisch B, Kouyos RD, Calmy A, Bucher HC, Cavassini M, Estill J, Keiser O, Egger M; Swiss HIV Cohort Study. Impact of screening and ART on anal cancer incidence in HIV-positive men who have sex with men: mathematical modeling study. AIDS. 2017 Aug 24;31(13):1859-1866.
12. Chimbetete C, Mugglin C, Shamu T, Kalesan B, Bertisch B, Egger M, Keiser O. New-Onset Type 2 Diabetes Mellitus Among Patients Receiving HIV Care At Newlands Clinic, Harare, Zimbabwe: Retrospective Cohort Analysis. Trop Med Int Health. 2017 Jul;22(7):839-845.
13. Zahnd C, Brezzi M, Bertisch B, Giudici F, Keiser O. Analyse de Situation des Hépatitis B et C en Suisse; sur mandat de l`Office fédéral de la santé publique. 2017 March 23.
14. Bertisch B, Giudici F, Negro F, Moradpour D, Müllhaupt B, Moriggia A, Estill J, Keiser O for the Swiss Hepatitis C Cohort Study. Characteristics of foreign-born persons in the Swiss Hepatitis C Cohort Study: implications for screening recommendations. PLoS One. 2016 May 26;11(5):e0155464.
15. Giudici F, Bertisch B, Negro F, Stirnimann G, Müllhaupt B, Moradpour D, Cerna A, Keiser O for the Swiss Hepatitis C Cohort Study. Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. J Viral Hep 2016 2016 Sep;23(9):697-707.
16. Zahnd C, Salazar-Vizcaya L, Dufour JF, Müllhaupt B, Wandeler G, Kouyos R, Estill J, Bertisch B, Rauch A, Keiser O; Swiss HIV and the Swiss Hepatitis C Cohort Studies. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. J Hepatol. 2016 Jul;65(1):26-32.
17. Clifford GM, Franceschi S, Keiser O, Schöni-Affolter F, Lise M, Dehler S, Levi F, Mousavi M, Bouchardy C, Wolfensberger A, Darling KE, Staehelin C, Bertisch B, Kuenzli E, Bernasconi E, Pawlita M, Egger M. Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study. Swiss HIV Cohort Study. Int J Cancer. 2016 Apr 1;138(7):1732-40.
18. Aebi-Popp K, Kouyos R, Bertisch B, Staehelin C, Rudin C, Hoesli I, Stoeckle M, Bernasconi E, Cavassini M, Grawe C, Lecompte TD, Rickenbach M, Thorne C, Martinez de Tejada B, Fehr J; Swiss Mother and Child HIV Cohort Study and the Swiss HIV Cohort Study. Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period. HIV Med. 2016 Apr;17(4):280-8.
19. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz- Baumgartner E, Báez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoger PH, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikic D, Mohn KG, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodríguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skręt-Magierło J, Stephan F, Talarek E, Tang JW, To KK, Torres A, T.rün SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RT, Zarogoulidis P; PRIDE Consortium Investigators, Nguyen-Van-Tam JS. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014 May;2(5):395-404.
20. Gueler A, Schoeni-Affolter F, Moser A, Bertisch B, Bucher HC, Calmy A, Cavassini M, Ledergerber B, Wandeler G, Egger M; Swiss HIV Cohort Study, Swiss National Cohort.AIDS.Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. 2015 Jan 14;29(2):231-8.
21. Aebi-Popp K, Kouyos R, Bertisch B, Staehelin C, Hoesli I, Rickenbach M, Thorne C, Grawe C, Bernasconi E, Cavassini M, de Tejada BM, Stoeckle M, Lecompte T, Rudin C, Fehr J. J Int AIDS Soc. Loss to follow-up of HIVinfected women after delivery: The Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort Study. 2014 Nov 2;17(4 Suppl 3):19535.
22. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz- Baumgartner E, Báez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoger PH, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikic D, Mohn KG, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodríguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skręt-Magierło J, Stephan F, Talarek E, Tang JW, To KK, Torres A, T.rün SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RT, Zarogoulidis P; PRIDE Consortium Investigators, Nguyen-Van-Tam JS. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014 May;2(5):395-404.
23. Bertisch B, Franceschi S, Lise M, Vernazza P, Keiser O, Schöni-Affolter F, Bouchardy C, Dehler S, Levi F, Jundt G, Ess S, Pawlita M, Kovari H, Wandeler G, Calmy A, Cavassini M, Stöckle M, and Clifford G for the Swiss HIV Cohort Study Investigators. Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study. Am J Epidemiology 2013; 178(6):877–884.
24. Aebi-Popp K, Mulcahy F, Glass T, Rudin C, Martinez de Tejada B, Bertisch B, Grawe C, Scheibner K, Hoesli I, Thorne C. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. JAIDS 2012; 15(6):18141.
25. Boillat Blanco N, Probst A, Da Costa VW, Giulieri S, Bernasconi E, Calmy A, Elzi L, Rauch A, Weber R, Bertisch B, Cavassini M, Bochud P-Y. Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic. J. Acquir. Immune Defic. Syndr. 2011 Dez;58(5):472–474.
26. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin. Infect. Dis. 2011 Dez;53(11):1130–1139.
27. Bertisch B, Vernazza P, Boggian K. Patients with influenza A/H1N1v-associated pneumonia: the perspective of a tertiary care hospital in Switzerland. SMW 2010;140:w13069.
28. Bihl F, Berger C, Chisholm JV 3rd, Henry LM, Bertisch B, Trojan A, Nadal D, Speck RF, Flepp M, Brander C, Mueller NJ. Cellular immune responses and disease control in acute AIDS-associated Kaposi’s sarcoma. AIDS 2009 Sep;23(14):1918–1922.
29. Cusini A, Günthard HF, Weber R, Huber M, Kamarashev J, Bertisch B, Peter S, Beck B. Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory syndrome in an HIV-1 infected patient after initiation of antiretroviral ther. BMJ Case Rep.2009.
30. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the SHCS. Antivir. Ther. 2007;12(6):931–939.
31. Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner EL. Interferon alpha 2a plus ribavirin 1.000/1.200 mg versus interferon alpha 2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005; 33:25-29.
32. Ulmer A, Müller M, Bertisch-Möllenhoff B, Frietsch B. Low-dose prednisolone has a CD4 stabilizing effect in pre-treated HIV patients during structured therapy interruptions. Eur J Med Res (2005) 10:227-232.
33. Ulmer A, Müller M, Bertisch-Möllenhoff B, Frietsch B. Low dose prednisolone reduces CD4+ T cell loss in therapy- naive HIV patients without antiretroviral therapy. Eur J Med Res (2005)10: 105-109.
34. Meili D, Marcinko J, Bertisch-Möllenhoff B, Huber M, Davatz F, Wang J. Mögliche Wege der Übertragung viraler Erkrankungen beim gemeinsamen Zubereiten von Drogen zum i.v. Konsum – Konsequenzen für die Prävention. Suchttherapie Supplement 2002; 3: S20-26.
35. Bertisch-Möllenhoff B, Meili D, Huber M: Nachweis von Hepatitis C-Viruslast in gebrauchten Heroinspritzen. Suchttherapie Supplement 2002; 3: S17-19.
Review, Editorial, Letter
36. Estill J, Bertisch B. More evidence for dolutegravir as first-line ART for all. Lancet HIV. 2020 Mar;7(3):e154-e155.
37. Clifford G, Bertisch B, Franceschi S. Clifford et al. Respond to “Biological and Clinical Insights From Epidemiologic Research Into HIV, HPV, and Anal Cancer”.Am J Epidemiol. 2013; 178(6):888-9.
38. Bertisch B, Grinsztejn B, Calmy A. HIV-infected women in Europe: gender-specific needs and challenges. Antiviral therapy 2013; 18(4): 549-51.
39. Bertisch B, Etter H, Frei M, Ruggia L, Vernazza P. Infektionserkrankungen bei Migranten in der Schweiz. Schweiz Med Forum 2012;12(33):624-627.
40. Bertisch B, Vernazza P. HIV-Infektion – Früherkennung verhindert Folgeschäden für Individuum und Gesellschaft. Schweiz Med Forum. 2010;A10(46):798-801.
41. Bertisch B, Ruef C. Pneumocystis-jiroveci-Pneumonie (PcP) bei Patienten mit rheumatologischen Erkrankungen. ZRheumatol 2006;65:18-23.
Poster
42. Brezzi M, Bertisch B, Moradpour D, Cerny A, Dufour JF, Heim M, Müllhaupt B, Semela D, Negro F, Keiser O. Influence of geographical origin on access to therapy and therapy outcomes in hepatitis C virus-infected persons: the Swiss Hepatitis C Cohort Study. Poster and Oral Presentation THU 098. EASL 2018 (Paris).
43. Bertisch B, Brezzi M, Negro F, Müllhaupt B, Künzler-Heule P, Schmid P, Clerc O, Moriggia A, Moradpour D, Keiser O. Very low hepatitis C viral loads in absence of therapy: impact on HCV antigen testing. Abstract/Poster 579, Croi 2018 (Boston).
44. Blaser N, Bertisch B, Koller M, Stoeckle M, Cavassini M, Kouyos R, Estill J, Egger M, Keiser O, for the Swiss HIV Cohort Study: Impact of ART coverage and screening on anal cancer in HIV+ men who have sex with men. Poster and Themed Discussion 596, Croi 2017 (Seattle).
45. Bertisch B, Giudici F, Keiser O. Characteristics of Foreign-Born Patients in the Swiss Hepatitis C Cohort Study: Implications for National Screening Recommendations. HepHIV 2014 Conference “Challenges of Timely Testing and Care” (Barcelona).
46. Bertisch B, Martin A, Rusch B, Vernazza P. Risk of occupational HIV, HBV and HCV transmission based on source patient infectiousness and exposure intensity -data from three Swiss hospitals. P 1625, ECCMID 2014 (Barcelona).
47. Bertisch B, Majer S, Steiner D, Herold M, Aebi-Popp K, Staehelin C. Women, let`s talk about our HIV! Declared Interest in Peer-support Group Participation in HIV-positive Women – a Survey in Swiss Treatment Centres. PE23/25, EACS 2013 (Brüssel).
48. Bertisch B, Tadros R, Rusch B, Vernazza P. Very Low Rate of VZV Susceptibility Among Newly EmployedPersonnel of a Swiss Hospital – a prevalence survey. P2437, ECCMID 2013 (Berlin).
49. Bertisch B, Tadros R, Rusch B, Vernazza P. Chronic Hepatitis B among the Personnel of three Swiss hospitals – a Seroprevalence Survey. P2210, ECCMID 2013 (Berlin).
50. Bertisch B, Tadros R, Rusch B, Vernazza P. Low Rate of Hepatitis C among the Personnel of a Swiss Hospital – a Seroprevalence Survey. P2224, ECCMID 2013 (Bertisch).
51. Bertisch B, Schöbi B, Lehmann T, Schlegel M. Hospital-wide evaluation of hand disinfectant tolerability: is sufficient good enough? 21st ECCMID 2011 und SGINF annual meeting 2011 (Mailand, Interlaken)
52. Polsfuss S, Bertisch B, Wieser S, Zbinden R. Isolation of Mycobacterium heckeshornense in an immunocompromised patient in Switzerland. 67th Ann. Ass. Swiss Soc. Microbiol., 2008.
Meinungsartikel in Schweizer (Fach-)Medien
53. Wingeier B, Avoledo P, Schmid-Thurneysen L, Zimmermann C, Schwendener C, Kiener L, Dietrich L, Iff M, Schmidt M, Grandinetti T, Perrenoud A, Möller R, Gutschner P, Riggenbach B, Bertisch B, Carp P, Capol S, Fröhlich J, Röllin A, Hug-Batschelet H, Fluri S, Streuli J, Meynard A, Etter G, Huber B, Tarr P. Sollen wir Kinder und Jugendliche gegen COVID-19 impfen? Prim Hosp Care Allg Inn Med. 2021;21(07):223-225.
54. Bertisch B. „Bedürfnis nach kleinen Auszeiten“, Leserbrief zu Covid-19. NZZ, 26.10.2020.
55. Interview Rütti N., Wirtschaftsredaktorin NZZ, mit Bertisch B. Warum der Arbeitsplatz wahrscheinlichkein Corona-Hotspot ist. NZZ, 31.10.2020.
56. Bertisch B. Covid-19 und Lärm. Gastkommentar. NZZ, 11.12.2020.
57. Bertisch B. Long Covid – wirklich ein Viertel befallen? Gastkommentar NZZ, 16.2.2021.
58. Bertisch B Selbsthilfe bei HIV-positiven Frauen.Schweiz Ärzteztg. 2018;99(34):1118-1119
Dissertation
59. Möllenhoff B: „Zur Frage der Beurteilungskriterien bei der sozialmedizinischen Begutachtung von Patienten mit seelischen und psychosomatischen Störungen“. Universität Münster, 1993.
Auszeichnung
“One of the ten papers of the year 2013 of the American Journal of Epidemiology”, für den Artikel “Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study”, Am. J. Epidemiology (s.o.)
Mitgliedschaften
- Schweizerische Gesellschaft für Infektiologie
- Deutsche Gesellschaft für Tropenmedizin und internationale Gesundheit
- HIV-Prakt (Zusammenschluss von niedergelassenen Ärzten in der HIV-Versorgung), Zürich
